MQS Management LLC Acquires New Position in Zimmer Biomet Holdings, Inc. $ZBH

MQS Management LLC acquired a new stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 5,376 shares of the medical equipment provider’s stock, valued at approximately $490,000.

A number of other hedge funds have also added to or reduced their stakes in the company. Chicago Partners Investment Group LLC grew its stake in shares of Zimmer Biomet by 3.3% during the second quarter. Chicago Partners Investment Group LLC now owns 3,865 shares of the medical equipment provider’s stock worth $376,000 after buying an additional 124 shares during the last quarter. Private Trust Co. NA lifted its holdings in Zimmer Biomet by 14.6% in the second quarter. Private Trust Co. NA now owns 1,073 shares of the medical equipment provider’s stock valued at $98,000 after buying an additional 137 shares during the period. Brooklyn Investment Group lifted its holdings in Zimmer Biomet by 45.9% in the first quarter. Brooklyn Investment Group now owns 461 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares during the period. IFP Advisors Inc lifted its holdings in Zimmer Biomet by 8.3% in the second quarter. IFP Advisors Inc now owns 1,947 shares of the medical equipment provider’s stock valued at $178,000 after buying an additional 149 shares during the period. Finally, Dakota Wealth Management lifted its holdings in Zimmer Biomet by 1.8% in the first quarter. Dakota Wealth Management now owns 9,791 shares of the medical equipment provider’s stock valued at $1,108,000 after buying an additional 171 shares during the period. 88.89% of the stock is owned by institutional investors.

Zimmer Biomet Trading Down 0.0%

NYSE:ZBH opened at $103.14 on Friday. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a 50-day moving average of $101.86 and a 200-day moving average of $97.68. The company has a market cap of $20.43 billion, a PE ratio of 25.09, a PEG ratio of 2.37 and a beta of 0.67. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion during the quarter, compared to the consensus estimate of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. The firm’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the previous year, the firm posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.9%. Zimmer Biomet’s payout ratio is presently 23.36%.

Analyst Ratings Changes

Several equities analysts recently issued reports on the stock. Rothschild Redb upgraded shares of Zimmer Biomet to a “strong-buy” rating in a report on Thursday, September 18th. Redburn Partners set a $130.00 price target on shares of Zimmer Biomet in a research note on Thursday, September 18th. UBS Group lifted their price target on shares of Zimmer Biomet from $91.00 to $96.00 and gave the company a “sell” rating in a research note on Friday, August 8th. Rothschild & Co Redburn initiated coverage on shares of Zimmer Biomet in a research note on Thursday, September 18th. They issued a “buy” rating and a $130.00 price target for the company. Finally, Stifel Nicolaus lifted their price target on shares of Zimmer Biomet from $115.00 to $118.00 and gave the company a “buy” rating in a research note on Friday, September 19th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eight have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $111.94.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of the business’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 1.39% of the stock is currently owned by insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.